Cereno Scientific's PAH drug candidate granted "Compassionate Use"

Cereno Scientific has been granted Expanded Access, also known as "Compassionate Use," by the FDA for drug candidate CS1 in rare disease pulmonary arterial hypertension. This will ensure that patients who have completed the ongoing phase II clinical study in PAH will have continued access to the drug. Cereno's CEO Sten R. Sörensen dropped by the BioStock Studio to talk about the importance of this decision.

0:00 Introduction
0:27 What is CS1
1:15 The phase II study in PAH
3:39 Positive patient case study data
9:03 Implications of Expanded Access
10:35 Great validation for CS1
12:20 Timeline for phase II study

Subscribe and follow BioStock on:
YouTube https://bit.ly/Biostock
LinkedIn:   / biostock  
Facebook:   / biostock.se  

https://www.biostock.se/
#BioStock #LifeScience #CerenoScientific

About BioStock
BioStock is Scandinavia's leading digital news and analysis service with an exclusive focus on the Life Science sector. Our primary editorial office and tv-studio is found at Medicon Village in Lund, one of Sweden's foremost innovation clusters for life science companies.